Pfizer and BioNTech Report Evidence That Their Vaccine Is Effective Against COVID-19 Variant
Vaccine partners Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) released information today that provides new evidence that their COVID-19 vaccine is effective against the B.1.1.7 variant that was initially detected in the United Kingdom and is believed to be more contagious than the original strain of the coronavirus.
Image source: Getty Images.
Pfizer and BioNTech conducted a laboratory study in which blood serum from trial subjects who had received the companies' BNT162b2 vaccine was exposed to pseudoviruses bearing either the spike protein of the original Wuhan strain or that of the B.1.1.7 variant. Pseudoviruses are synthesized in a laboratory to mimic true viruses but are safer to handle because they can only replicate once.
Source Fool.com
